Imunon (IMNN) Q2 FY26 earnings call

Imunon reported strong Q2 FY26 results, highlighted by the accelerated enrollment in its pivotal Phase 3 Ovation 3 study, significantly outpacing internal assumptions and industry benchmarks. This momentum is underpinned by continued positive clinical validation of Immunon 001, including compelling final overall survival data from Phase 2 Ovation 2 and encouraging preliminary data from the Phase 2 MRD trial. While the company demonstrates disciplined financial management, securing additional capital remains a key focus to fully fund the ongoing Phase 3 program.